Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 21:04:00 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Scandion Oncology Q2 2023 - CORIST part 3 data around the corner

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Scandion Oncology Q2 2023 - CORIST part 3 data around the corner

2023-08-23 16:49:00

Redeye comments on Scandion Oncology’s Q2 2023 report, and we judge that CORIST part 4 data in 2024e is the primary catalyst for the company’s share in the coming 12-18 months. Further, we believe CORIST part 3 top-line data in H2 2023e and more granular PANTAX data in Q4 2023e-H1 2024e might provide minor catalysts. We do some housekeeping in our model.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/